Vimarsana
Biggest News Aggregation in the World

Page 14 - Acceleron Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acceleron Pharma Today - Breaking & Trending Today

Is Merck Stock a Top Buy Right Now? | The Motley Fool - Vimarsana News

Is Merck Stock a Top Buy Right Now? | The Motley Fool

The drugmaker is still a work in progress.

Source: fool.com
Got $5,000? Buy These 2 Stocks and Hold Them Until Retirement - Vimarsana News

Got $5,000? Buy These 2 Stocks and Hold Them Until Retirement

Not every familiar name is a company you can comfortably tuck away in your portfolio for decades, but these two are.

Source: fool.com
Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors - Vimarsana News

Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual...

Alkermes plc: Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors - Vimarsana News

Alkermes plc: Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

Sarissa's Proposed Candidates Would Not Bring New Skills to the Board Recommends Shareholders Vote "FOR" Alkermes' Director Nominees on Company's WHITE Proxy Card DUBLIN, June 13,

Luspatercept 'a paradigm shift' in transfusion-dependent myelodysplastic syndrome - Vimarsana News

Luspatercept 'a paradigm shift' in transfusion-dependent myelodysplastic syndrome

Treatment with luspatercept vs. epoetin alfa nearly doubled the number of patients with lower-risk myelodysplastic syndrome who no longer required red blood cell transfusions for anemia, results of the phase 3 COMMANDS trial showed.The findings, scheduled for presentation at ASCO Annual Meeting, showed luspatercept (Reblozyl; Celgene, Bristol Myers Squibb) — an erythroid maturation agent

Source: healio.com